People Born Without Growth Hormone Have Unique IGF-1 Patterns and Avoid Heart Disease

A Brazilian cohort with congenital growth hormone deficiency shows altered IGF-I bioavailability yet maintains normal lifespan without premature atherosclerosis.

Campos, Viviane C et al.·European journal of endocrinology·2026·
RPEP-149302026RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Congenital isolated GH-deficient individuals show severely reduced IGF-I and IGFBP-3 but altered IGF-I bioavailability, associated with no premature atherosclerosis and normal lifespan despite metabolic risk factors.

Key Numbers

How They Did This

Characterization of IGF-I bioavailability in the Itabaianinha cohort with homozygous GHRH receptor mutation causing congenital isolated GH deficiency.

Why This Research Matters

Understanding why GH-deficient people avoid heart disease despite metabolic risk factors could reveal new pathways for cardiovascular protection in the general population.

The Bigger Picture

This natural experiment suggests that the growth hormone/IGF-I axis plays a more complex role in cardiovascular disease than previously thought, with potential implications for longevity research.

What This Study Doesn't Tell Us

Unique genetic cohort — findings may not generalize to acquired GH deficiency or GH-normal populations. Small cohort inherent to rare genetic condition.

Questions This Raises

  • ?Could modulating IGF-I bioavailability reduce cardiovascular disease in normal populations?
  • ?Is the cardiovascular protection due to low GH, altered IGF-I, or other compensatory mechanisms?

Trust & Context

Key Stat:
No heart disease despite risk factors Congenital GH deficiency with obesity and high cholesterol but no premature atherosclerosis
Evidence Grade:
Unique natural experiment cohort — provides extraordinary biological insights but from a rare, non-generalizable population.
Study Age:
Published in 2026; continues long-running research on this unique Brazilian cohort.
Original Title:
IGF-I bioavailability in congenital isolated growth hormone deficiency.
Published In:
European journal of endocrinology, 194(2), 136-145 (2026)
Database ID:
RPEP-14930

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

How can people without growth hormone avoid heart disease?

Despite obesity and high cholesterol, these individuals with congenital GH deficiency have altered IGF-I patterns that may protect their blood vessels from atherosclerosis — suggesting GH/IGF-I signaling plays a complex role in heart disease.

Could this help develop anti-aging treatments?

The Itabaianinha cohort's cardiovascular protection despite metabolic risk factors is of great interest to longevity researchers, as it suggests manipulating GH/IGF-I pathways could promote healthy aging.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-14930·https://rethinkpeptides.com/research/RPEP-14930

APA

Campos, Viviane C; Aguiar Oliveira, Manuel H; Bidlingmaier, Martin; Yuen, Kevin C J; Salvatori, Roberto; Oliveira, Carla R P; Leal, Angela; Melo, Enaldo; Schilbach, Katharina; Frystyk, Jan; Schweizer, Júnia R O L. (2026). IGF-I bioavailability in congenital isolated growth hormone deficiency.. European journal of endocrinology, 194(2), 136-145. https://doi.org/10.1093/ejendo/lvag007

MLA

Campos, Viviane C, et al. "IGF-I bioavailability in congenital isolated growth hormone deficiency.." European journal of endocrinology, 2026. https://doi.org/10.1093/ejendo/lvag007

RethinkPeptides

RethinkPeptides Research Database. "IGF-I bioavailability in congenital isolated growth hormone ..." RPEP-14930. Retrieved from https://rethinkpeptides.com/research/campos-2026-igfi-bioavailability-in-congenital

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.